TG Therapeutics Inc (NASDAQ: TGTX) has experienced a rise in its stock price by 2.32 compared to its previous closing price of 13.78. However, the company has seen a gain of 0.21% in its stock price over the last five trading days. Seeking Alpha reported 2024-04-12 that TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023, with positive market feedback and significant revenue. The company has strong barriers to entry and patent protection for BRIUMVI, allowing for potential growth in 2024 and 2025.
Is It Worth Investing in TG Therapeutics Inc (NASDAQ: TGTX) Right Now?
TG Therapeutics Inc (NASDAQ: TGTX) has a higher price-to-earnings ratio of 1000.00x compared to its average ratio. TGTX has 36-month beta value of 2.31. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TGTX is 139.66M, and currently, short sellers hold a 24.60% ratio of that float. The average trading volume of TGTX on April 23, 2024 was 3.54M shares.
TGTX’s Market Performance
The stock of TG Therapeutics Inc (TGTX) has seen a 0.21% increase in the past week, with a -7.54% drop in the past month, and a -13.07% fall in the past quarter. The volatility ratio for the week is 4.68%, and the volatility levels for the past 30 days are at 4.11% for TGTX. The simple moving average for the past 20 days is -3.89% for TGTX’s stock, with a 2.46% simple moving average for the past 200 days.
Analysts’ Opinion of TGTX
Many brokerage firms have already submitted their reports for TGTX stocks, with Goldman repeating the rating for TGTX by listing it as a “Neutral.” The predicted price for TGTX in the upcoming period, according to Goldman is $12 based on the research report published on August 02, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TGTX reach a price target of $40, previously predicting the price at $55. The rating they have provided for TGTX stocks is “Buy” according to the report published on June 26th, 2023.
BofA Securities gave a rating of “Underperform” to TGTX, setting the target price at $5 in the report published on May 20th of the previous year.
TGTX Trading at -6.73% from the 50-Day Moving Average
After a stumble in the market that brought TGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.47% of loss for the given period.
Volatility was left at 4.11%, however, over the last 30 days, the volatility rate increased by 4.68%, as shares sank -8.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.69% lower at present.
During the last 5 trading sessions, TGTX rose by +0.21%, which changed the moving average for the period of 200-days by -38.80% in comparison to the 20-day moving average, which settled at $14.60. In addition, TG Therapeutics Inc saw -17.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TGTX starting from Lonial Sagar, who sale 5,000 shares at the price of $15.94 back on Mar 13 ’24. After this action, Lonial Sagar now owns 108,878 shares of TG Therapeutics Inc, valued at $79,675 using the latest closing price.
Charney Laurence N, the Director of TG Therapeutics Inc, sale 22,000 shares at $15.97 during a trade that took place back on Mar 12 ’24, which means that Charney Laurence N is holding 215,229 shares at $351,340 based on the most recent closing price.
Stock Fundamentals for TGTX
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.94 for the gross margin
The net margin for TG Therapeutics Inc stands at 0.06. The total capital return value is set at 0.07. Equity return is now at value 11.57, with 4.84 for asset returns.
Based on TG Therapeutics Inc (TGTX), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -0.31. The debt to equity ratio resting at 0.63. The interest coverage ratio of the stock is 1.64.
Currently, EBITDA for the company is 21.06 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 9.39. The receivables turnover for the company is 4.57for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.92.
Conclusion
To put it simply, TG Therapeutics Inc (TGTX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
